Powered by

Castle Biosciences Presents Data on DecisionDx-Melanoma at the Virtual European Association of Dermato-Oncology (EADO) Congress; Prospective, multi-center study data support use of DecisionDx®-Melanoma in T1-T2 melanoma patients 65 years and older to iden

Oct 16, 2020 - Business Wire

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of data demonstrating that DecisionDx®-Melanoma identifies patients with T1-T2 melanoma who have a low risk of sentinel lymph node (SLN) positivity. DecisionDx-Melanoma is Castle's gene expression profile test that uses an individual patient's tumor biology to predict individual risk of cutaneous melanoma me...